☰

Conor McClenaghan - Publications

Affiliations: 
2011-2015 Physics (and Physiology) University of Oxford, Oxford, United Kingdom 
 2022- Pharmacology & Medicine Rutgers - Robert Wood Johnson Medical School 
Tree Info Grants Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Efthymiou S, Scala M, Nagaraj V, Ochenkowska K, Komdeur FL, Liang RA, Abdel-Hamid MS, Sultan T, Barøy T, Van Ghelue M, Vona B, Maroofian R, Zafar F, Alkuraya FS, Zaki MS, ... ... McClenaghan C, et al. Novel loss-of-function variants expand ABCC9-related intellectual disability and myopathy syndrome. Brain : a Journal of Neurology. PMID 38217872 DOI: 10.1093/brain/awae010  0.365
2023 Gao J, McClenaghan CG, Matreyek K, Grange DK, Nichols CG. . The Journal of Pharmacology and Experimental Therapeutics. PMID 37527933 DOI: 10.1124/jpet.123.001659  0.442
2023 McClenaghan C, Mukadam MA, Roeglin J, Tryon RC, Grabner M, Dayal A, Meyer GA, Nichols CG. Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS. Embo Molecular Medicine. e16883. PMID 37154692 DOI: 10.15252/emmm.202216883  0.434
2023 Scala R, Maqoud F, McClenaghan C, Harter TM, Perrone MG, Scilimati A, Nichols CG, Tricarico D. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome. Cells. 12. PMID 36980269 DOI: 10.3390/cells12060928  0.335
2022 Gao J, McClenaghan C, Christiaans I, Alders M, van Duinen K, van Haelst MM, van Haaften G, Nichols CG. Lymphedema as first clinical presentation of Cantu Syndrome: reversed phenotyping after identification of gain-of-function variant in ABCC9. European Journal of Human Genetics : Ejhg. PMID 36336713 DOI: 10.1038/s41431-022-01210-x  0.454
2022 McClenaghan C, Nichols CG. Kir6.1 and SUR2B and Cantú syndrome. American Journal of Physiology. Cell Physiology. PMID 35876283 DOI: 10.1152/ajpcell.00154.2022  0.5
2021 Singareddy SS, Roessler HI, McClenaghan C, Ikle JM, Tryon RC, van Haaften G, Nichols CG. ATP-sensitive potassium channels in zebrafish cardiac and vascular smooth muscle. The Journal of Physiology. PMID 34820842 DOI: 10.1113/JP282157  0.648
2021 Zhang H, Hanson AM, Scherf de Almeida TU, Emfinger CH, McClenaghan C, Harter T, Yan Z, Cooper PE, Brown GS, Arakel EC, Mecham RP, Kovacs A, Halabi CM, Schwappach B, Remedi MS, et al. Complex consequences of Cantu Syndrome SUR2 variant R1154Q in genetically modified mice. Jci Insight. PMID 33529173 DOI: 10.1172/jci.insight.145934  0.476
2020 Scala R, Maqoud F, Zizzo N, Mele A, Camerino GM, Zito FA, Ranieri G, McClenaghan C, Harter TM, Nichols CG, Tricarico D. Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome. Frontiers in Pharmacology. 11: 604885. PMID 33329006 DOI: 10.3389/fphar.2020.604885  0.462
2020 McClenaghan C, Hanson A, Lee SJ, Nichols CG. Coronavirus Proteins as Ion Channels: Current and Potential Research. Frontiers in Immunology. 11: 573339. PMID 33154751 DOI: 10.3389/fimmu.2020.573339  0.417
2020 McClenaghan C, Huang Y, Matkovich SJ, Kovacs A, Weinheimer CJ, Perez R, Broekelmann TJ, Harter TM, Lee JM, Remedi MS, Nichols CG. The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome. Function (Oxford, England). 1: zqaa004. PMID 32865539 DOI: 10.1093/function/zqaa004  0.459
2020 Maqoud F, Scala R, Mele A, McClenaghan C, Remedi MS, Nichols CC, Tricarico D. Biophysical and Pharmacological Characterization of Atp-Sensitive Potassium Channels in Mice Kir6.1WT/V65M Mirroring the Human Cantu′ Syndrome Biophysical Journal. 118. DOI: 10.1016/J.Bpj.2019.11.3195  0.592
2020 Singareddy SS, Roessler HI, McClenaghan C, Tryon RC, van Haaften G, Nichols CG. KATP Channels in Zebrafish Cardiovascular System: A Model to Study Cantú Syndrome Biophysical Journal. 118: 259a. DOI: 10.1016/J.Bpj.2019.11.1503  0.622
2019 Grange DK, Roessler HI, McClenaghan C, Duran K, Shields K, Remedi MS, Knoers NVAM, Lee JM, Kirk EP, Scurr I, Smithson SF, Singh GK, van Haelst MM, Nichols CG, van Haaften G. Cantú syndrome: Findings from 74 patients in the International Cantú Syndrome Registry. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 181: 658-681. PMID 31828977 DOI: 10.1002/Ajmg.C.31753  0.441
2019 McClenaghan C, Huang Y, Yan Z, Harter T, Halabi CM, Chalk R, Kovacs A, van Haaften G, Remedi MS, Nichols CG. Glibenclamide reverses cardiovascular abnormalities of Cantu Syndrome driven by KATP channel overactivity. The Journal of Clinical Investigation. PMID 31821173 DOI: 10.1172/Jci130571  0.633
2019 Smeland MF, McClenaghan C, Roessler HI, Savelberg S, Hansen GÅM, Hjellnes H, Arntzen KA, Müller KI, Dybesland AR, Harter T, Sala-Rabanal M, Emfinger CH, Huang Y, Singareddy SS, Gunn J, et al. ABCC9-related Intellectual disability Myopathy Syndrome is a K channelopathy with loss-of-function mutations in ABCC9. Nature Communications. 10: 4457. PMID 31575858 DOI: 10.1038/S41467-019-12428-7  0.519
2019 Ma A, Gurnasinghani S, Kirk EP, McClenaghan C, Singh GK, Grange DK, Pandit C, Zhou Y, Roscioli T, Elakis G, Buckley M, Mehta B, Roberts P, Mervis J, Biggin A, et al. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience. American Journal of Medical Genetics. Part A. PMID 31175705 DOI: 10.1002/Ajmg.A.61200  0.384
2019 McClenaghan C, Woo KV, Nichols CG. Pulmonary Hypertension and ATP-Sensitive Potassium Channels. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA11912. PMID 31132951 DOI: 10.1161/Hypertensionaha.119.12992  0.51
2019 McClenaghan C, Huang Y, Halabi C, Harter T, Mecham RP, Remedi MS, Nichols CG. The Mechanism of Cardiovascular Pathophysiology in Cantu Syndrome and Response to Glibenclamide in Novel KATP Channel Mutant Mouse Models Biophysical Journal. 116: 31a. DOI: 10.1016/J.Bpj.2018.11.209  0.56
2018 Huang Y, McClenaghan C, Harter TM, Hinman K, Halabi CM, Matkovich SJ, Zhang H, Brown GS, Mecham RP, England SK, Kovacs A, Remedi MS, Nichols CG. Cardiovascular consequences of KATP overactivity in Cantu syndrome. Jci Insight. 3. PMID 30089727 DOI: 10.1172/Jci.Insight.121153  0.447
2018 McClenaghan C, Huang Y, Harter T, Brown GS, Hinman K, Halabi C, Matkovich S, Mecham RP, Weinheimer CJ, Kovacs A, England S, Remedi MS, Nichols CG. Abstract 011: Cardiovascular Consequences of Cantu Syndrome and Response to Glibenclamide Treatment in Two Novel KATP Channel Mutant Mouse Models Arteriosclerosis, Thrombosis, and Vascular Biology. 38. DOI: 10.1161/Atvb.38.Suppl_1.011  0.53
2017 McClenaghan C, Hanson A, Sala-Rabanal M, Roessler HI, Josifova D, Grange DK, van Haaften G, Nichols CG. Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms. The Journal of Biological Chemistry. PMID 29275331 DOI: 10.1074/Jbc.Ra117.000351  0.568
2017 Cooper PE, McClenaghan C, Chen X, Stary-Weinzinger A, Nichols CG. Conserved functional consequences of disease-associated mutations in the slide-helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel. The Journal of Biological Chemistry. PMID 28842488 DOI: 10.1074/Jbc.M117.804971  0.53
2017 Aryal P, Jarerattanachat V, Clausen MV, Schewe M, McClenaghan C, Argent L, Conrad LJ, Dong YY, Pike AC, Carpenter EP, Baukrowitz T, Sansom MS, Tucker SJ. Bilayer-Mediated Structural Transitions Control Mechanosensitivity of the TREK-2 K2P Channel. Structure (London, England : 1993). PMID 28392258 DOI: 10.1016/J.Str.2017.03.006  0.705
2016 McClenaghan C, Schewe M, Aryal P, Carpenter EP, Baukrowitz T, Tucker SJ. Polymodal activation of the TREK-2 K2P channel produces structurally distinct open states. The Journal of General Physiology. 147: 497-505. PMID 27241700 DOI: 10.1085/Jgp.201611601  0.724
2016 McClenaghan C, Schewe M, Baukrowitz T, Tucker SJ. Polymodal Gating of the TREK-2 K2P Potassium Channel Involves Structurally Distinct Open States Biophysical Journal. 110: 607. DOI: 10.1016/J.Bpj.2015.11.3241  0.745
2015 Dong YY, Pike AC, Mackenzie A, McClenaghan C, Aryal P, Dong L, Quigley A, Grieben M, Goubin S, Mukhopadhyay S, Ruda GF, Clausen MV, Cao L, Brennan PE, Burgess-Brown NA, et al. K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. Science (New York, N.Y.). 347: 1256-9. PMID 25766236 DOI: 10.1126/Science.1261512  0.736
2015 McClenaghan C, Carpenter E, Stephen TJ. Mechanisms of TREK-2 Potassium Channel Gating Biophysical Journal. 108. DOI: 10.1016/J.Bpj.2014.11.2386  0.656
2014 Pike A, Dong Y, Mackenzie A, McClenaghan C, Mukhopadhyay S, Burgess-Brown N, Tucker S, Carpenter E. Structures of the human two-pore domain potassium channels TREK-1 and TREK-2 Acta Crystallographica Section A. 70. DOI: 10.1107/S2053273314085106  0.685
2012 McClenaghan C, Zeng F, Verkuyl JM. TRPA1 agonist activity of probenecid desensitizes channel responses: consequences for screening. Assay and Drug Development Technologies. 10: 533-41. PMID 22681402 DOI: 10.1089/Adt.2012.447  0.396
Show low-probability matches.